Proactive Investors - Run By Investors For Investors

Brain Scientific says Super Bowl ad study finds Microsoft scored with its Xbox ‘We All Win’ spot

Using Brain Scientific’s NeuroCap EEG cap to measure brain activity, a lab analyzed the most effective and memorable commercials
Brain Scientific device
Microsoft's 'We All Win' ad showcased the Xbox Adaptive Controller

Brain Scientific Inc said Friday that a lab deploying its brain-monitoring device found that the “We All Win” commercial from Microsoft Corp (NASDAQ:MSFT) promoting the Xbox Adaptive Controller was the most effective Super Bowl LIII spot.

Marketing Brainology invited consumers into its neuroscience research lab to measure the impact of various Super Bowl ads, Brain Scientific, a New York-based health sciences technology company, said in a statement.

READ: Netflix unveils Super Bowl surprise with Cloverfield release

Using Brain Scientific’s NeuroCap electroencephalogram (EEG) cap to measure brain activity, along with eye-tracking software, Marketing Brainology was able to analyze responsive biomarkers and determine the most effective and memorable commercials aired during the game.

“Thanks to Brain Scientific’s NeuroCap, we are able to better understand the art and science of the human decision-making process,” said Michelle Adams, the founder of Marketing Brainology. “Marketing departments can use this data to better connect with consumers before allocating millions of dollars in producing a commercial.”

The ad for the Xbox Adaptive Controller featured several children with disabilities.

Contact Dennis Fitzgerald at [email protected]

View full BRSF profile View Profile

Brain Scientific Timeline

Related Articles

PT exercises
December 19 2018
The Californian company is a bet on an industry that is in need of transformation
cancer scan
January 03 2019
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult
April 12 2019
The biotechnology company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused by chronic naproxen use
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use